Guías Clínicas 51 Guía de hepa titis c - M. Umar et al. infection-2003. J Pak Med Assoc 2004; 54: 146-50. Available at: http://www.psg.org.pk/new/PSGHCV.pdf. 38.- Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401. 39.- Tanaka Y, Nishida N, Sugiyama M, et al. Genomewide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9. 40.- Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53: 325-35. 41.- Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44. Available at: http://www. aasld.org/practiceguidelines/Documents/2011UpdateGen otype1HCVbyAASLD24641.pdf. 42.- Omata M, Kanda T, Yu ML. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012; 6: 409-36. Available at: http://www.chinesefms.com/doc/zhw/zxdt/201203/ P020120321562034553835.pdf. 43.- Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32 Suppl 1: 88-102. 44.- Beinhardt S, Staettermayer AF, Rutter K, et al. Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias? Hepatology 2012; 55: 30- 8. 45.- Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol 2012; 26: 359-75. 46.- Hussain AB, Hussain T, Anwar M, et al. Treatment response in HCV related chronic hepatitis. J Coll Physicians Surg Pak 2004; 14: 466-9. 47.- Qureshi S, Batool U, Iqbal M, et al. Response rates to standard interferon treatment in HCV genotype 3a. J Ayub Med Coll Abbottabad 2009; 21: 10-4. 48.- Ho SH, Ng KP, Ngeow YF, Kamarudin R. Genotypic manifestation of hepatitis C virus in a multi-ethnic society of Malaysia abstract. J Gastroenterol Hepatol 2012; 27 (Suppl 5): P02-20. 49.- Yu ML, Huang CF, Huang JF, et al. Role of interleukin- 28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53: 7-13. 50.- Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009; 24: 336-45. 51.- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64. Gastroenterol. latinoam 2015; Vol 26, Nº 1: 30-51
n12015
To see the actual publication please follow the link above